Brain tumor vaccine links mutation targeting to eight-year survival gains

Researchers have published long-term results from a clinical trial showing that a peptide vaccine targeting a specific IDH1 mutation can improve survival rates for patients with high-grade astrocytomas. The vaccine works by training the immune system to recognize and attack tumor cells carrying the mutation.